For incidence calculations, we calculated survival during the interval so that it was the product of the probability of surviving to the interval without a diagnosis of breast cancer and the probability of not getting incident breast cancer during the interval.
For patients that were deceased, we calculated survival time as the time from enrollment to the date of death.
To investigate whether the higher mortality is continued in the C-HP group we calculated survival until the endpoint of our experimental setting (360 days).
For every individual strain, we calculated survival averages for each independent experiment (biological repeat) and these data were used to calculate the P values of the different slopes and the different ploidy clusters.
Using information in the Medicare file we calculated survival times as the period from surgery to the date of death.
During the follow-up, we calculated survival as time from baseline initiation to syphilis seroconversion or censoring.
